ArticleEClinicalMedicine2023

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial.

Xiaofei Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.